Letter to the Editor

In a recent article in The Journal for Nurse Practitioners,1 the authors robustly presented the clinical trial data evidence, mechanism of action (MOA), use, and prescribing of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in heart failure (HF).
Source: The Journal for Nurse Practitioners - Category: Nursing Authors: Tags: Letter to the Editor Source Type: research